found that azacytidine (Aza) in combination with ITF-2357 could stimulate IFNα/β pathway related genes and suppress MYC signaling to reverse immune evasion and activate T cell phenotypes in non-small-cell lung cancer (NSCLC) patients, indicating that the combination of epigenetic treatments can have a potent anti-tumor effect (74). Here, MYC is linked to non-small cell lung carcinoma.